LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

43.7 3.33

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

41.15

Max

44.4

Põhinäitajad
By Trading Economics
Sissetulek	-14M -105M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	-15M -104M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+28.91% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-13M 3.3B
Eelmine avamishind	40.37
Eelmine sulgemishind	43.7

Uudiste sentiment

By Acuity

50%

158 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. märts 2026, 18:43 UTC

Uudisväärsed sündmused

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3. märts 2026, 17:33 UTC

Omandamised, ülevõtmised, äriostud

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3. märts 2026, 23:45 UTC

Market Talk

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3. märts 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3. märts 2026, 23:25 UTC

Market Talk

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3. märts 2026, 23:25 UTC

Market Talk

Global Energy Roundup: Market Talk

3. märts 2026, 22:38 UTC

Uudisväärsed sündmused

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3. märts 2026, 22:16 UTC

Tulu

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3. märts 2026, 22:09 UTC

Tulu

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3. märts 2026, 22:06 UTC

Tulu

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3. märts 2026, 22:05 UTC

Tulu

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3. märts 2026, 22:03 UTC

Tulu

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Tech, Media & Telecom Roundup: Market Talk

3. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

3. märts 2026, 21:45 UTC

Uudisväärsed sündmused

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3. märts 2026, 21:37 UTC

Tulu

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3. märts 2026, 21:26 UTC

Uudisväärsed sündmused

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3. märts 2026, 20:31 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3. märts 2026, 20:04 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3. märts 2026, 19:17 UTC

Market Talk

Uudisväärsed sündmused

Gold and Silver Drop as Energy Surges -- Market Talk

3. märts 2026, 18:43 UTC

Tulu

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3. märts 2026, 18:29 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

3. märts 2026, 18:29 UTC

Market Talk

Uudisväärsed sündmused

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3. märts 2026, 18:22 UTC

Uudisväärsed sündmused

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3. märts 2026, 18:22 UTC

Uudisväärsed sündmused

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3. märts 2026, 18:17 UTC

Market Talk

Uudisväärsed sündmused

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3. märts 2026, 18:14 UTC

Tulu

How Long Can Anthropic Play Defense? -- WSJ

3. märts 2026, 17:41 UTC

Uudisväärsed sündmused

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3. märts 2026, 17:36 UTC

Uudisväärsed sündmused

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3. märts 2026, 17:28 UTC

Omandamised, ülevõtmised, äriostud

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

28.91% tõus

12 kuu keskmine prognoos

Keskmine 56.45 USD 28.91%

Kõrge 66 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

158 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.